혈액암 (AML/ALL)

CGTBiologicstaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

AntibodystaleImmunityBio, Inc.Phase 3

atezolizumab (Tecentriq, Cisplatin/carboplatin and pemetrexed plus atezolizumab.)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2

AntibodystaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, Cisplatin/carboplatin and pemetrexed plus pembrolizumab.)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2

ADCBiologicstaleEverett MeyerPhase 2

CliniMACS CD34 Reagent System (CliniMACS CD34 Reagent System)

Leukemia, Acute; Chronic Myelogenous Leukemia (CML) · CD3

#CD3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4

AntibodystaleIdris BahceApproved

durvalumab (Imfinzi, Consolidation durvalumab)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Approved#항체#면역항체+2

AntibodystaleUniversity of Texas Southwester…Phase 2

durvalumab (Imfinzi, Consolidative Durvalumab)

Non Small Cell Lung Cancer; Lung Cancer Stage III · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

CGTBiologicstaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

AntibodystaleDong-A ST Co., Ltd.Phase 2

pembrolizumab (Keytruda, DA-4505 + Pembrolizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase2#항체#면역항체+2

AntibodystaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

CGTBiologicstaleShanghai General Hospital, Shan…Phase 1

Dasatinib plus anti-CD19/CD22 CAR-T cells (Dasatinib plus anti-CD19/CD22 CAR-T cells)

Ph Positive ALL; CAR-T Cell · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

AntibodystaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4

AntibodystaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#항체#면역항체+2

효능 ORR 0%임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Docetetaxel (Docetetaxel)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

AntibodystaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3

CGTBiologicstaleMasonic Cancer Center, Universi…Phase 2

Donor TCR α/β-depleted Graft/ATG (Donor TCR α/β-depleted Graft/ATG)

Acute Myeloid Leukemia; Myelodysplastic Syndrome · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3

CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5

CGTBiologicstaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4